Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ibio Inc IBIO

Healthcare Biotechnology
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

Recent & Breaking News (NYSEAM:IBIO)

Another iBio Plague Vaccine Patent Issues

Marketwired November 21, 2016

iBio Expands Product Development Capacity of cGMP Plant

Marketwired November 10, 2016

iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd

Marketwired September 29, 2016

Implications of Court Decision in Favor of iBio Against Fraunhofer

Marketwired August 15, 2016

iBio, Inc.'s Claims Against Fraunhofer Affirmed by Delaware Chancery Court

Marketwired August 4, 2016

iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate

Marketwired July 5, 2016

Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals

Marketwired June 7, 2016

iBio, Inc. Holds Annual Meeting in College Station, Texas

Marketwired April 7, 2016

iBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment

Marketwired January 14, 2016

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of iBio, Inc. -- IBIO

GlobeNewswire January 8, 2016

iBio Continues Global Expansion of Intellectual Property

Marketwired November 30, 2015

Scientific Insights Into IBIO-CFB03 Presented at American College of Rheumatology Annual Meeting

Marketwired November 19, 2015

iBio European Protein Expression Patent Emerges From Opposition Period

Marketwired October 27, 2015

New Chinese iBioModulator(TM) Patent Joins iBio Vaccine Portfolio

Marketwired September 30, 2015

iBio Anti-Fibrosis Portfolio Expanded to Include Orally Delivered Peptides

Marketwired September 21, 2015

iBio's Robert Erwin Interviewed by The Life Sciences Report

Marketwired September 10, 2015

iBio Fibrosis Therapeutics Program Receives NIH Grant Support

Marketwired September 9, 2015

iBio to Receive US Patent for Influenza Therapeutic

Marketwired August 11, 2015

Three Recent iBioLaunch(TM) Platform Achievements to Be Presented at PBVAB 2015 Conference in Lausanne, Switzerland

Marketwired June 8, 2015

Vaccine Improvement Patent Awarded to iBio

Marketwired May 4, 2015